INTERNATIONAL SOCIETY FOR DISEASES OF THE ESOPHAGUS
Barrett's esophagus is a very common premalignant lesion affecting between 2-3% of the adult population in the West. As a consequence strategies have evolved to attempt to abrogate the progression along the metaplasia-dysplasia-adenocarcinoma sequence. Several strategies including earlier detection, screening and surveillance have an unproven efficacy. As a consequence the role of chemoprevention agents (drugs which can prevent cancer) has come to the fore. The prime agent is aspirin but the risk-benefit ratio remains unclear. In addition it isn't clear who will respond best and who will be destined for life threatening complications. Genomics may be able to tease this out.
© International Society for Diseases of the Esophagus 2016